Plain-English translation of NCT06441357 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This research study is testing whether a special type of CT scan โ called dual energy CT โ can help doctors identify how aggressive a lung adenocarcinoma is by measuring something called extracellular volume (ECV). The goal is to find out whether this imaging measurement can reliably tell the difference between early-stage lung cancers that are less likely to spread and more advanced cancers that are more invasive.
Right now, doctors sometimes have difficulty predicting which lung adenocarcinomas will be aggressive and which will stay slow-growing, which can lead to unnecessary surgery or delayed treatment. This study hopes to find a better imaging tool that could help doctors make smarter, more personalized treatment decisions for patients with lung adenocarcinoma.
You will receive a specialized dual energy CT scan of your chest, which uses contrast dye to create detailed images. The scan itself is a quick, painless procedure similar to a regular CT scan. Your doctors will measure the extracellular volume in the images and compare it with your actual cancer stage (determined by pathology) to see if this imaging measurement can predict how invasive your cancer is.
AI-generated summary from trial data ยท Jun 24, 2026 ยท Not medical advice
China
Sponsor
Tang-Du Hospital
Enrollment target
~2,000 participants
Started
June 2024
Primary completion
December 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Cui Guangbin, Professor
ang-Du Hospital